Walgreen Co.'s prescriptions and profits may get a boost from flu season, Medicare drug plans and the health care overhaul, according to a Jefferies analyst who raised his rating on the drugstore chain's shares.
The Deerfield, Ill., company's cost savings from its acquisition of a stake in European health and beauty retailer Alliance Boots have also been faster than expected, said analyst Scott A. Mushkin said in a Monday research note.
He raised his rating on the stock to "Buy" from "Hold" and increased his price target to $47 from $40.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
